Spun out of the University of Cambridge, T-Therapeutics leverages its proprietary OpTiMus discovery platform to create TCR-CD3 bispecific drugs that precisely target pathogenic immune cells. Its lead oncology candidate addresses a pan-tumour driver target applicable across multiple solid tumours, while its lead immunology program is a pan-autoimmune bispecific designed to reset the immune system by selectively depleting harmful T-cell subsets. The company is also exploring new therapeutic strategies such as T-cell subset depletion to broaden its clinical impact. Management is headed by CEO Theodora Harold. To date, T-Therapeutics has secured a total of $91 million in Series A financing, providing runway to advance its pipeline toward first-in-human studies. The fresh capital is earmarked for moving these programs into the clinic and expanding discovery efforts across oncology and autoimmune indications.

Total raised

$92M

Funding rounds

2

Latest round

Series A

Latest activity

Nov 2025